Pyxis Oncology (PYXS) Cash & Current Investments (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Cash & Current Investments data on file, last reported at $16.9 million in Q4 2025.

• Cash & Current Investments for Q4 2025 came in at $16.9 million, down 19.34% year-over-year; the trailing twelve-month figure through Dec 2025 was $16.9 million (down 19.34% YoY), and the FY2025 annual result was $16.9 million, down 19.34% from the prior year.
• Cash & Current Investments rose to $16.9 million in Q4 2025 per PYXS's latest filing, from $10.4 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $276.2 million in Q4 2021 and troughed at $10.4 million in Q3 2025.
• A 5-year average of $116.0 million and a median of $126.1 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2021 and 2024: Cash & Current Investments soared 1086.88% in 2021, then tumbled 89.83% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $276.2 million in 2021, then slumped by 34.55% to $180.8 million in 2022, then sank by 34.0% to $119.3 million in 2023, then plunged by 82.44% to $20.9 million in 2024, then dropped by 19.34% to $16.9 million in 2025.
• Business Quant data shows PYXS's Cash & Current Investments at $16.9 million in Q4 2025, $10.4 million in Q3 2025, and $88.9 million in Q2 2025.